Chronic myeloid leukemia in myeloid blast phase (acute myeloid leukemia)
Conditions
Interventions
Tyrosine kinase inhibitor combined with hypomethylating agent group:None
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged 18 years and over; 2.Chronic myeloid leukemia in myeloid blast phase resistant or intolerant to at least one type of TKI; 3.No severe dysfunction of heart, lung, liver or kidney; 4.Be able to understand and voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects with a history of severe cardiological or cerebral disease; 2. Subjects who have received allogeneic hematopoietic stem cell transplantation; 3. Severe uncontrollable infection; 4. Subjects known to be allergic to the drug used in this study; 5. Pregnant or lactating female, or Subjects with a pregnancy plan during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major hematologic response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete hematologic response;Major cytogenetic response;Major cytogenetic response;Progression free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactJiang Qian
Peking University People's Hospital
Outcome results
None listed